Contract Award

Deltex Medical Group PLC
18 January 2007



                            Deltex Medical Group plc

                  CardioQ(TM) to be evaluated by US Army in Iraq


18 January 2007 Deltex Medical Group plc ('Deltex Medical' or the 'Company'),
the UK's leading haemodynamic monitoring company, today announces that the US
army in Iraq are to embark on an evaluation of the Company's CardioQ monitor.

Six monitors and an initial stock of probes have been ordered by the US Army for
use at a combat support hospital in Iraq. The monitors will be used to guide
fluid management in trauma patients transferring to and undergoing surgery at
the hospital.

Deltex Medical's chief executive, Andy Hill, commented:

'The use of the CardioQ in trauma patients, whether in a combat setting or
following a road-traffic accident, represents a significant opportunity for
Deltex Medical.

Trauma patients frequently suffer from life-threatening blood-loss, either
internally or externally, that requires rapid assessment and immediate
intervention. The CardioQ looks directly at blood flow, rather than relying on
less sensitive pressure-based parameters, which gives it a fundamental
technological advantage over other monitoring systems and makes it ideally
suited for this application.

The CardioQ is the only haemodynamic monitor proven to improve outcomes when
used during surgery, where similar rapid changes in haemodynamics are seen. We
fully expect that this work by the US army will report similar improvements in
outcome in patients undergoing surgery for trauma based on this work.'


For further information, please contact:-

Deltex Medical Group plc                   Tel: [phone]

Nigel Keen, Chairman
[e-mail]

Andy Hill, Chief Executive
[e-mail]

Ewan Phillips, Finance Director
[e-mail]

 
Gavin Anderson & Company                   Tel: [phone]

Deborah Walter             
[e-mail]

Robert Speed                
[e-mail]

Marie Cairney                
[e-mail]


Charles Stanley Securities                 Tel: [phone]

Philip Davies                                                           
[e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.


The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-


   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.


                      This information is provided by RNS
            The company news service from the London Stock Exchange